Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016; 18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.
Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative.
AMA J Ethics. 2019; 21(7):E587-593. doi:
10.1001/amajethics.2019.587.